US Pharma MarketingThe post Sanofi & Teva’s IBD drug prompts long-term clinical remission in Phase IIb trial appeared first on Clinical Trials Arena.
Sanofi & Teva’s IBD drug prompts long-term clinical remission in Phase IIb trial
Analysts say that Sanofi and Teva's duvakitug could be differentiated from other pipeline TL1A candidates as the race to market heats up. Analysts say that duvakitug could be differentiated from other pipeline TL1A candidates as the race to market heats up. Duvakitug is one of several anti-TL1A therapies currently in development for inflammatory bowel diseases like Crohn’s and ulcerative colitis. Credit: MMD Creative / Shutterstock.com. Sanofi and Teva Pharmaceuticals’ inflammatory bowel disease (IBD) drug has shown benefit in patients with both ulcerative colitis (UC) and Crohn’s disease. The companies have debuted new data from a mid-stage study, which has highlighted…
Analysts say that Sanofi and Teva's duvakitug could be differentiated from other pipeline TL1A candidates as the race to market heats up.
Source: Clinical Trials Arena